Stem cells tested for a tough Crohn's complication – but trial stopped early
NCT ID NCT04519697
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether stem cells from donated bone marrow could safely heal rectovaginal fistulas in women with Crohn's disease. These fistulas are abnormal connections between the rectum and vagina that cause pain, infections, and poor quality of life. The trial planned to enroll 20 women but was terminated early, so we don't have clear results on whether the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- allogeneic bone marrow derived mesenchymal stem cells
- What this could lead to
- If successful, this approach could offer a new way to heal rectovaginal fistulas in Crohn's disease, potentially reducing pain and improving quality of life.
- What could go wrong
- This was a very early (Phase 1/2) trial with only 20 participants, and it was terminated early, so we have limited data on safety and effectiveness. Stem cell treatments also carry risks like infection or immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
20 people
The number who actually took part.
- Started
-
Oct 2020
- Finished
-
Nov 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Females 18-75 years of age with a diagnosis of Crohn's disease for at least six months duration. 2. Single-tract, rectovaginal fistula in the setting of Crohn's disease. 3. Have no contraindications to MR evaluations: e.g. pacemaker or magnetically active metal fragments, claustrophobia 4. Ability to comply with protocol 5. Competent and able to provide written informed consent, and ability to comply with protocol 6. Concurrent Crohn's related therapies with stable doses (\>2 months) corticosteroids, 5-ASA drugs, immunomodulators, anti-TNF therapy, anti-integrin and anti-interleukin are permitted Exclusion Criteria: 1. Inability to give informed consent. 2. Clinically significant medical conditions within the six months before administration of MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the subject. 3. Specific exclusions: 1. Hepatitis B or C 2. HIV 3. Abnormal AST or ALT at screening(defined as \>/= 2x ULN) 4. History of cancer including melanoma (with the exception of localized skin cancers) within one year of screening. 5. History of colorectal cancer within 5 years. 6. Investigational drug within 30 days of treatment 7. Pregnant or breast feeding or trying to become pregnant. 8. Presence of a rectovaginal or perineal body fistula 9. Change in Crohn's immunosuppressive regimen within the 2 months prior to enrollment 10. Uncontrolled intestinal Crohn's disease which will require escalation for medical therapy or surgery within 2 months of enrollment 11. Severe anal canal disease that is stenotic and requires dilation 12. Inability to wean corticosteroids 13. Unwilling to agree to use acceptable contraception methods during participation in study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Crohn disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune aging blood tests predict which older IBD patients thrive on advanced therapies?
- Can a liquid diet calm Crohn's in kids?
- Which IBD therapy works best for kids? researchers compare two approaches
- Can trained peer mentors ease the mental toll of IBD?
- Can a new pill tame inflammatory bowel disease?
- Can diet and blood tests predict IBD Flare-Ups?